Literature DB >> 20101679

Acute lymphoblastic leukemia in Weaver syndrome.

Lina Basel-Vanagaite1.   

Abstract

Weaver syndrome comprises pre- and postnatal overgrowth, accelerated osseous maturation, characteristic craniofacial appearance and developmental delay; it is a generally sporadic disorder, although autosomal dominant inheritance has been reported. Some of the manifestations characterize both the Weaver and Sotos syndrome, and distinction between the two is mainly by clinical examination and molecular testing. Most of the patients with Sotos syndrome have NSD1 gene deletions or mutations; however, the molecular basis of most of the Weaver syndrome patients is unknown. Patients with overgrowth syndromes have an increased frequency of tumors; the risk in Sotos syndrome patients has been estimated to be about 2-3%, with leukemia and lymphoma accounting for 44% of the malignancies. We report on a 4(1/2)-year-old girl with typical Weaver syndrome who developed acute lymphoblastic leukemia, an association not previously reported, and review the reported cases of Weaver syndrome patients who developed malignancies. Malignancy in Weaver syndrome has been reported previously in six patients. While searching the literature for all reported cases with Weaver syndrome and counting the cases with malignancy, we found that the frequency of tumors or hematologic malignancy was 10.9%. This is likely to be an overestimate, biased by failure to report cases without tumors and by over-reporting cases with this rare association. While the presence of acute lymphoblastic leukemia in our patient might be incidental, we cannot exclude a possible causative association between Weaver syndrome and hematologic malignancy. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101679     DOI: 10.1002/ajmg.a.33244

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  6 in total

Review 1.  Genetic syndromes caused by mutations in epigenetic genes.

Authors:  María Berdasco; Manel Esteller
Journal:  Hum Genet       Date:  2013-01-31       Impact factor: 4.132

Review 2.  A Clinical Review of Generalized Overgrowth Syndromes in the Era of Massively Parallel Sequencing.

Authors:  Benjamin Kamien; Anne Ronan; Gemma Poke; Ingrid Sinnerbrink; Gareth Baynam; Michelle Ward; William T Gibson; Tracy Dudding-Byth; Rodney J Scott
Journal:  Mol Syndromol       Date:  2018-01-25

3.  Mutations in EZH2 cause Weaver syndrome.

Authors:  William T Gibson; Rebecca L Hood; Shing Hei Zhan; Dennis E Bulman; Anthony P Fejes; Richard Moore; Andrew J Mungall; Patrice Eydoux; Riyana Babul-Hirji; Jianghong An; Marco A Marra; David Chitayat; Kym M Boycott; David D Weaver; Steven J M Jones
Journal:  Am J Hum Genet       Date:  2011-12-15       Impact factor: 11.025

4.  Ezh2 Mutations Found in the Weaver Overgrowth Syndrome Cause a Partial Loss of H3K27 Histone Methyltransferase Activity.

Authors:  Julian C Lui; Kevin M Barnes; Lijin Dong; Shanna Yue; Evan Graber; Robert Rapaport; Andrew Dauber; Ola Nilsson; Jeffrey Baron
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

5.  Co-occurrence of a maternally inherited DNMT3A duplication and a paternally inherited pathogenic variant in EZH2 in a child with growth retardation and severe short stature: atypical Weaver syndrome or evidence of a DNMT3A dosage effect?

Authors:  Katarzyna Polonis; Patrick R Blackburn; Raul A Urrutia; Gwen A Lomberk; Teresa Kruisselbrink; Margot A Cousin; Nicole J Boczek; Nicole L Hoppman; Dusica Babovic-Vuksanovic; Eric W Klee; Pavel N Pichurin
Journal:  Cold Spring Harb Mol Case Stud       Date:  2018-08-01

Review 6.  Diagnostic Approach to Macrocephaly in Children.

Authors:  Andrea Accogli; Ana Filipa Geraldo; Gianluca Piccolo; Antonella Riva; Marcello Scala; Ganna Balagura; Vincenzo Salpietro; Francesca Madia; Mohamad Maghnie; Federico Zara; Pasquale Striano; Domenico Tortora; Mariasavina Severino; Valeria Capra
Journal:  Front Pediatr       Date:  2022-01-14       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.